Unparalleled rare cannabinoid expertise
InMed is a leader in the manufacturing, development and commercialization of rare cannabinoids. Our manufacturing technologies produce several rare cannabinoids for pharmaceutical development and consumer products.
Producing rare cannabinoids for a variety of uses
InMed’s rare cannabinoids are being applied across a spectrum of uses – from pharmaceutical development to wholesale sales to the consumer health and wellness sector. Our pharmaceutical programs include a Phase 2 clinical program in dermatology and a preclinical program in glaucoma. Our portfolio also includes a growing library of patentable rare cannabinoid analogs for development. In addition, our division, BayMedica, produces highly pure rare cannabinoids d9-THCV, CBC, CBDV and CBT for the consumer health and wellness industry.
Unlocking the Therapeutic Potential of Rare Cannabinoids
Rare cannabinoids are an emerging class of compounds which are gaining interest for their potential medical benefits. InMed has initiated two pharmaceutical programs – a Phase 2 clinical trial for epidermolysis bullosa, a rare genetic skin disease, and has begun preparing to initiate clinical studies in glaucoma following promising preclinical results.
A Portfolio of Rare Cannabinoids for the Health and Wellness Sector
InMed’s subsidiary, BayMedica, is producing a portfolio of premium rare cannabinoids as raw ingredients for your health and wellness products. We have engineered bioidentical cannabinoids with high purity and consistency, and free of THC. We currently manufacture the rare, minor cannabinoids tetrahydrocannabivarin (d9-THCV) cannabidivarin (CBDV), cannabichromene (CBC) and cannabicitran (CBT) which are available for B2B purchase.